Polypill is a fixed dose drug combination used in the treatment of various chronic diseases. This combination pharmacotherapy offers the potential to decrease the incidence and prevalence of cardiovascular and other diseases. Polypill improves patient compliance, thereby increasing the adoption of these products. This is likely to boost the growth of the global polypill products market. Moreover, ease of dosage understanding for elderly patients and increase in usage of polypill products are the major advantages offered by polypill products over other formulations. Combination therapy is more effective than a single substance with an acceptable safety profile.
This report contains market size and forecasts of Polypill Products in Global, including the following market information:
Global Polypill Products Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Polypill Products market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cardiovascular Diseases Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Polypill Products include Pfizer, Inc., AstraZeneca, Merck & Co, Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Dr. Reddy’s Laboratories Ltd., Cipla, Inc., Cadila Pharmaceuticals, Grupo Ferrer International and Takeda Pharmaceutical Company Limited, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Polypill Products companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Polypill Products Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Polypill Products Market Segment Percentages, by Type, 2021 (%)
Cardiovascular Diseases
Diabetes Mellitus
Anti-infective
Others
Global Polypill Products Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Polypill Products Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Polypill Products Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Polypill Products Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Polypill Products revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Polypill Products revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer, Inc.
AstraZeneca
Merck & Co
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Dr. Reddy’s Laboratories Ltd.
Cipla, Inc.
Cadila Pharmaceuticals
Grupo Ferrer International
Takeda Pharmaceutical Company Limited
Gebro Pharma GmbH
Gilead Sciences, Inc.